Effects of zoledronic acid on proteinase plasma levels in patients with bone metastases

Anticancer Research

Volumn 26, Issue 1 A, 2006, Pages 23-26

  Leto, Gaetano ^a   Badalamenti, Giuseppe ^a   Arcara, Carlo ^a   Crescimanno, Marilena ^a   Flandina, Carla ^a   Tumminello, Francesca Maria ^a   Incorvaia, Lorena ^a   Gebbia, Nicola ^a   Fulfaro, Fabio ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

Bisphosphonates; Bone metastasis; Cathepsin B; Matrix metalloproteinase 2; Matrix metalloproteinase 9; Proteinases; Urokinase type plasminogen activator; Zoledronic acid

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CATHEPSIN B; CYSTEINE PROTEINASE; GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE; PROTEINASE; UROKINASE; ZOLEDRONIC ACID;

ADULT; AGED; ANALGESIC ACTIVITY; ARTICLE; BONE METASTASIS; BONE PAIN; BREAST CANCER; CLINICAL ARTICLE; CORRELATION COEFFICIENT; DRUG EFFECT; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; PATHOGENESIS; PRIORITY JOURNAL; PROSTATE CANCER; SYMPTOMATOLOGY; VISUAL ANALOG SCALE;

AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; BREAST NEOPLASMS; CATHEPSIN B; DIPHOSPHONATES; FEMALE; HUMANS; IMIDAZOLES; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; PROSTATIC NEOPLASMS; URINARY PLASMINOGEN ACTIVATOR;

EID: 32144439404     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Neville-Webbe HL and Coleman RE: The use of zoledronic acid in the management of metastatic bone disease and hypercalcemia. Palliat Med 17(6): 539-553, 2003.
2. Green JR: Bisphosphonates: preclinical review. Oncologist 9(suppl 4): 3-13, 2004.
3. Boissier S, Ferreras M, Peyruchaud, Magnetto S, Ebetino FH, Colombel M, Delmas P, Delaissé JM and Clézardin P: Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res 60: 2949-2954, 2000.
4. Corey E, Brown LG, Quinn JA, Poot M, Roudier MP, Higano CS and Vessella RL: Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer. Clin Cancer Res 9: 295-306, 2003.
5. Bonfil RD, Osenkowski P, Fridman R and Cher ML: Matrix metalloproteinases and bone metastasis. Cancer Treat Res 118: 173-195, 2004.
6. Fulfaro F, Casuccio A, Ticozzi C and Ripamonti C: The role of bisphosphonates in the treatment of painful metastatic bone disease a review of phase III trials. Pain 78: 157-169, 1998.
7. Heidenreich A: Bisphosphonates in the management of metastatic prostate cancer. Oncology 65(Suppl 1): 5-11, 2003.
8. Keller ET. The role of osteoclastic activity in prostate cancer skeletal metastasis. Drugs Today 38(2): 91-102, 2002.
9. Fulfaro F, Leto G, Badalamenti G, Arcara C Cicero G, Valerio MR, Di Fede G, Russo A, Intrivici C, Rini GB, Casuccio A and Gebbia N: The use of zoledronic acid in patients with bone metastases from prostate carcinoma: effects on analgesic response and bone metabolism markers. J Chemother 17(5): 555-559, 2005.
10. Podgorski I, Linebaugh BE, Sameni M, Jedeszko C, Bhagat S, Cher ML and Sloane BF: Bone microenvironment modulates expression and activity of cathepsin B in prostate cancer. Neoplasia 7(3): 207-223, 2005.
11. Ohta S, Fuse H, Fujiuchi Y, Nagakawa O and Furuya Y: Clinical significance of expression of urokinase-type plasminogen activator in patients with prostate cancer. Anticancer Res 23(3C): 2945-2950, 2003.
12. World Medical Association Declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. JAMA 277: 925-926, 1997.
13. Serlin RC, Mendoza TR, Nakamura Y, Edwards KR and Cleeland CS: When is cancer pain mild moderate or severe? Grading pain severity by its interference with function. Pain 61: 277-284, 1995.
14. MEDCALC version 7.4. Copyright 1993-2004; Frank Schoonjans, http://www.medcalc.be
15. Skrzydlewska E, Sulkowska M, Koda M and Sulkowski S: Proteolytic- antiproteolytic balance and its regulation in carcinogenesis. World J Gastroenterol 11(9): 1251-1266, 2005.
16. Delaissé JM, Andersen T, Engsig MT, Henriksen K, Troen T and Blavier L: Matrix metalloproteinases and Cathepsin K contribute differently to osteoclastic activities. Microsc Res Tech 61: 504-513, 2005.
17. Hart CA, Scott LJ, Bagley S, Bryden AA, Clarke NW and Lang SH: Role of proteolytic enzymes in human prostate bone metastasis formation: in vivo and in vitro studies. Br J Cancer 86(7): 1136-1142, 2002.
18. Everts V, Delaissé JM, Korper W and Beertsen W: Cysteine proteinases and matrix metalloproteinases play a distinct role in the subosteoclastic resorption zone. J Bone Miner Res 13: 1420-1430, 1998.
19. Podgorski I and Sloane BF: Cathepsin B and its role(s) in cancer progression. Biochem Soc Symp 70: 263-276, 2003.
20. Dong Z, Bonfil RD, Chinni S , Deng X, Trindade Filho JC, Bernardo M, Vaishampayan U, Che M, Sloane BF, Sheng S, Fridman R and Cher ML: Matrix metalloproteinase activity and osteoclasts in experimental prostate cancer bone metastasis tissue. Am J Pathol 166(4): 1173-1186, 2005.
21. Goto T, Yamaza T and Tanaka T: Cathepsins in the osteoclast. J Electron Microsc 52(6): 551-558, 2003.
22. Geoffroy V, Marty-Morieux C, Le Goupil N, Clement-Lacroix P, Terraz C, Frain M, Roux S, Rossert J and de Vernejoul MC: In vivo inhibition of osteoblastic metalloproteinases leads to increased trabecular bone mass. J Bone Miner Res 19(5): 811-822, 2004.
23. Lee ER, Lamplugh L, Shepard NL and Mort JS: The septoclast, a cathepsin B-rich cell involved in the resorption of growth plate cartilage. J Histochem Cytochem 43: 525-536, 1995.
24. Derenne S, Amiot M, Barillè S, Collette M, Robillard N, Berthaud P, Harousseau JL and Bataille R: Zoledronate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMP-1 by the tumoral environment. J Bone Miner Res 14(12): 2048-2056, 1999.